Alzheimer's drug trial halted after early safety check

NCT ID NCT06247345

Terminated Disease control Sponsor: Alzheimer's Disease Expert Lab (ADEL), Inc. Source: ClinicalTrials.gov ↗

First seen Nov 18, 2025 · Last updated May 01, 2026 · Updated 19 times

Summary

This early-stage study tested a new drug called ADEL-Y01 in healthy volunteers and people with mild Alzheimer's or mild cognitive impairment. The goal was to check safety, side effects, and how the drug moves through the body. The trial was stopped early, so results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Accel Research - Neurostudies

Decatur, Georgia, 30030, United States
CenExel ACT

Anaheim, California, 92801, United States
Innovation Medical Research

Palmetto Bay, Florida, 33157, United States
K2 Medical Research - Orlando

Maitland, Florida, 32751, United States
K2 Medical Research - The Villages

Lady Lake, Florida, 32159, United States
Quest Research Institute

Farmington Hills, Michigan, 48334, United States

Conditions

Explore the condition pages connected to this study.

ALZHEIMER DISEASE